The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Open accessAbstract
BACKGROUND: Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments. OBJECTIVES: To compare the efficacy and safety of low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) for the long-term treatment of venous thromboembolism (VTE) in people with cancer. SEARCH METHODS: We conducted a literature search including a major electronic search of the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), MEDLINE (Ovid), and Embase (Ovid); handsearching conference proceedings; checking references of included studies; use of the 'related citation' feature in PubMed and a search for ongoing studies in trial registries. As part of the living systematic review approach, we run searches continually, incorporating new evidence after it is identified. Last search date 14 May 2018. SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the benefits and harms of long-term treatment with LMWHs, DOACs or VKAs in people with cancer and symptomatic VTE. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on study characteristics and risk of bias. Outcomes included: all-cause mortality, recurrent VTE, major bleeding, minor bleeding, thrombocytopenia, and health-related quality of life (QoL). We assessed the certainty of the evidence at the outcome level following the GRADE approach (GRADE handbook). MAIN RESULTS: Of 15,785 citations, including 7602 unique citations, 16 RCTs fulfilled the eligibility criteria. These trials enrolled 5167 people with cancer and VTE.Low molecular weight heparins versus vitamin K antagonistsEight studies enrolling 2327 participants compared LMWHs with VKAs. Meta-analysis of five studies probably did not rule out a beneficial or harmful effect of LMWHs compared to VKAs on mortality up to 12 months of follow-up (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.88 to 1.13; risk difference (RD) 0 fewer per 1000, 95% CI 45 fewer to 48 more; moderate-certainty evidence). Meta-analysis of four studies did not rule out a beneficial or harmful effect of LMWHs compared to VKAs on major bleeding (RR 1.09, 95% CI 0.55 to 2.12; RD 4 more per 1000, 95% CI 19 fewer to 48 more, moderate-certainty evidence) or minor bleeding (RR 0.78, 95% CI 0.47 to 1.27; RD 38 fewer per 1000, 95% CI 92 fewer to 47 more; low-certainty evidence), or thrombocytopenia (RR 0.94, 95% CI 0.52 to 1.69). Meta-analysis of five studies showed that LMWHs probably reduced the recurrence of VTE compared to VKAs (RR 0.58, 95% CI 0.43 to 0.77; RD 53 fewer per 1000, 95% CI 29 fewer to 72 fewer, moderate-certainty evidence).Direct oral anticoagulants versus vitamin K antagonistsFive studies enrolling 982 participants compared DOACs with VKAs. Meta-analysis of four studies may not rule out a beneficial or harmful effect of DOACs compared to VKAs on mortality (RR 0.93, 95% CI 0.71 to 1.21; RD 12 fewer per 1000, 95% CI 51 fewer to 37 more; low-certainty evidence), recurrent VTE (RR 0.66, 95% CI 0.33 to 1.31; RD 14 fewer per 1000, 95% CI 27 fewer to 12 more; low-certainty evidence), major bleeding (RR 0.77, 95% CI 0.38 to 1.57, RD 8 fewer per 1000, 95% CI 22 fewer to 20 more; low-certainty evidence), or minor bleeding (RR 0.84, 95% CI 0.58 to 1.22; RD 21 fewer per 1000, 95% CI 54 fewer to 28 more; low-certainty evidence). One study reporting on DOAC versus VKA was published as abstract so is not included in the main analysis.Direct oral anticoagulants versus low molecular weight heparinsTwo studies enrolling 1455 participants compared DOAC with LMWH. The study by Raskob did not rule out a beneficial or harmful effect of DOACs compared to LMWH on mortality up to 12 months of follow-up (RR 1.07, 95% CI 0.92 to 1.25; RD 27 more per 1000, 95% CI 30 fewer to 95 more; low-certainty evidence). The data also showed that DOACs may have shown a likely reduction in VTE recurrence up to 12 months of follow-up compared to LMWH (RR 0.69, 95% CI 0.47 to 1.01; RD 36 fewer per 1000, 95% CI 62 fewer to 1 more; low-certainty evidence). DOAC may have increased major bleeding at 12 months of follow-up compared to LMWH (RR 1.71, 95% CI 1.01 to 2.88; RD 29 more per 1000, 95% CI 0 fewer to 78 more; low-certainty evidence) and likely increased minor bleeding up to 12 months of follow-up compared to LMWH (RR 1.31, 95% CI 0.95 to 1.80; RD 35 more per 1000, 95% CI 6 fewer to 92 more; low-certainty evidence). The second study on DOAC versus LMWH was published as an abstract and is not included in the main analysis.Idraparinux versus vitamin K antagonistsOne RCT with 284 participants compared once-weekly subcutaneous injection of idraparinux versus standard treatment (parenteral anticoagulation followed by warfarin or acenocoumarol) for three or six months. The data probably did not rule out a beneficial or harmful effect of idraparinux compared to VKAs on mortality at six months (RR 1.11, 95% CI 0.78 to 1.59; RD 31 more per 1000, 95%
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Samama, M. M., Cohen, A. T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.-G., Turpie, A. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411103 · Cited by 1,584
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Leizorovicz, A., Cohen, A. T., Turpie, A. G. G., Olsson, C.-G., Vaitkus, P. T., & Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000138928.83266.24 · Cited by 955
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Levitan, N., Dowlati, A., Remick, S. C., Tahsildar, H. I., Sivinski, L. D., Beyth, R., & Rimm, A. A. (1999) · Medicine · doi:10.1097/00005792-199909000-00001 · Cited by 891
Cohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Hutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., & Büller, H. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3078 · Cited by 748
Lee, A. Y. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., & for the CATCH Investigators (2015) · JAMA · doi:10.1001/jama.2015.9243 · Cited by 614
Hull, R. D., Pineo, G. F., Brant, R. F., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.-C., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.022 · Cited by 607
Clinical expertise in the era of evidence-based medicine and patient choice
Haynes, R. B. (2002) · Evidence-Based Medicine · doi:10.1136/ebm.7.2.36 · Cited by 586
Agnelli, G., Piovella, F., Buoncristiani, P., Severi, P., Pini, M., D'Angelo, A., Beltrametti, C., Damiani, M., Andrioli, G. C., Pugliese, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390204 · Cited by 523
SCHULMAN, S., LINDMARKER, P., HOLMSTRÖM, M., LÄRFARS, G., CARLSSON, A., NICOL, P., SVENSSON, E., LJUNGBERG, B., VIERING, S., NORDLANDER, S., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01795.x · Cited by 507
Deep vein thrombosis of the leg
Kakkar, V. V., Howe, C. T., Nicolaides, A. N., Renney, J. T. G., & Clarke, M. B. (1970) · The American Journal of Surgery · doi:10.1016/s0002-9610(70)80023-x · Cited by 477
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
Schulman, S., Wåhlander, K., Lundström, T., Clason, S. B., & Eriksson, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030104 · Cited by 454
Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., & Levine, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.133 · Cited by 453
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P. (2001) · Circulation · doi:10.1161/01.cir.103.20.2453 · Cited by 408
Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 394
Deitcher, S. R., Kessler, C. M., Merli, G., Rigas, J. R., Lyons, R. M., & Fareed, J. (2006) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029606293692 · Cited by 392
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Kavanagh, D. O., Chambers, G., O' Grady, L., Barry, K. M., Waldron, R. P., Bennani, F., Eustace, P. W., & Tobbia, I. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-1 · Cited by 367
Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P., et al. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649783 · Cited by 353
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Dettori, J. (2011) · Evidence-Based Spine-Care Journal · doi:10.1055/s-0030-1267080 · Cited by 336
Couban, S., Goodyear, M., Burnell, M., Dolan, S., Wasi, P., Barnes, D., MacLeod, D., Burton, E., Andreou, P., & Anderson, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.192 · Cited by 331
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6844 · Cited by 323
Verso, M., Agnelli, G., Bertoglio, S., Di Somma, F. C., Paoletti, F., Ageno, W., Bazzan, M., Parise, P., Quintavalla, R., Naglieri, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.084 · Cited by 303
Fiessinger, J.-N., Huisman, M. V., Davidson, B. L., Bounameaux, H., Francis, C. W., Eriksson, H., Lundström, T., Berkowitz, S. D., Nyström, P., Thorsén, M., et al. (2005) · JAMA · doi:10.1001/jama.293.6.681 · Cited by 295
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Prins, M. H., Lensing, A. W. A., Brighton, T. A., Lyons, R. M., Rehm, J., Trajanovic, M., Davidson, B. L., Beyer-Westendorf, J., Pap, Á. F., Berkowitz, S. D., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70018-3 · Cited by 283
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Pelzer, U., Opitz, B., Deutschinoff, G., Stauch, M., Reitzig, P. C., Hahnfeld, S., Müller, L., Grunewald, M., Stieler, J. M., Sinn, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1481 · Cited by 268
Clinical expertise in the era of evidence-based medicine and patient choice
(2002) · ACP Journal Club · doi:10.7326/acpjc-2002-136-2-a11 · Cited by 249
Alikhan, R., Cohen, A. T., Combe, S., Samama, M. M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C.-G., & Turpie, A. G. (2003) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200306000-00004 · Cited by 244
Nurmohamed, M. T., van Riel, A. M., Henkens, C. M. A., Koopman, M. M. W., Que, G. T. H., D’Azemar, P., Büller, H. R., ten Cate, J. W., Hoek, J. A., van der Meer, J., et al. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650250 · Cited by 242
Legnani, C., Lee, A., Manotti, C., Hirsh, J., D’Angelo, A., Pengo, V., Moia, M., Coccheri, S., & Palareti, G. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614120 · Cited by 221
Pini, M., Aiello, S., Manotti, C., Pattacini, C., Quintavalla, R., Poli, T., Tagliaferri, A., & Dettoi, A. G. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648837 · Cited by 218
Posch, F., Königsbrügge, O., Zielinski, C., Pabinger, I., & Ay, C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.011 · Cited by 215
Agnelli, G., Buller, H. R., Cohen, A., Gallus, A. S., Lee, T. C., Pak, R., Raskob, G. E., Weitz, J. I., & Yamabe, T. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13153 · Cited by 197
Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis
Goldhaber, S. Z., Dunn, K., Gerhard-Herman, M., Park, J. K., & Black, P. M. (2002) · Chest · doi:10.1378/chest.122.6.1933 · Cited by 193
Wildner, M. (1995) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.77b4.7615617 · Cited by 186
Macbeth, F., Noble, S., Evans, J., Ahmed, S., Cohen, D., Hood, K., Knoyle, D., Linnane, S., Longo, M., Moore, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0268 · Cited by 178
Lack of Effect of Coumarin in Women with Lymphedema after Treatment for Breast Cancer
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Rooke, T. W., Quella, S. K., Novotny, P., Mowat, R. B., Michalak, J. C., Stella, P. J., Levitt, R., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400503 · Cited by 178
Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O’Rourke, K., Wells, G., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.733 · Cited by 174
Massicotte, P., Julian, J. A., Gent, M., Shields, K., Marzinotto, V., Szechtman, B., & Andrew, M. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00059-8 · Cited by 168
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer
Goldhaber, S. Z., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Hantel, S., Feuring, M., Kreuzer, J., & Schulman, S. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0977 · Cited by 159
Akl, E. A., Johnston, B. C., Alonso‐Coello, P., Neumann, I., Ebrahim, S., Briel, M., Cook, D. J., & Guyatt, G. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057132 · Cited by 157
Self-citationvan der Heijden, J. F., Hutten, B. A., Buller, H. R., & Prins, M. H. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002001 · Cited by 154
Das, S. K., Cohen, A. T., Edmondson, R., Melissari, E. N., & Kakkar, V. V. (1996) · World Journal of Surgery · doi:10.1007/s002689900081 · Cited by 151
Iorio, A., Guercini, F., & Pini, M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00364.x · Cited by 143
Zwicker, J. I., Liebman, H. A., Bauer, K. A., Caughey, T., Campigotto, F., Rosovsky, R. P. G., Mantha, S. H., Kessler, C. M., Eneman, J. D., Raghavan, V. R., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12163 · Cited by 142
Ebrahim, S., Akl, E. A., Mustafa, R. A., Sun, X., Walter, S. D., Heels-Ansdell, D., Alonso-Coello, P., Johnston, B. C., & Guyatt, G. H. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.03.014 · Cited by 141
Self-citationBielska-Fałda, H., Noszczyk, W., Bielawiec, M., Witkiewicz, W., Filipecki, S., Michalak, J., Ciesielski, L., Mackiewicz, Z., Częstochowska, E., Zawilska, K., et al. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614412 · Cited by 140
López-Beret, P., Orgaz, A., Fontcuberta, J., Doblas, M., Martinez, A. C., Lozano, G., & Romero, A. (2001) · Journal of Vascular Surgery · doi:10.1067/mva.2001.109336 · Cited by 129
Alshurafa, M., Briel, M., Akl, E. A., Haines, T., Moayyedi, P., Gentles, S. J., Rios, L., Tran, C., Bhatnagar, N., Lamontagne, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049163 · Cited by 126
Self-citationVerso, M., Agnelli, G., Kamphuisen, P. W., Ageno, W., Bazzan, M., Lazzaro, A., Paoletti, F., Paciaroni, M., Mosca, S., & Bertoglio, S. (2008) · Internal and Emergency Medicine · doi:10.1007/s11739-008-0125-3 · Cited by 126
González-Fajardo, J. A., Arreba, E., Castrodeza, J., Pérez, J. L. G., Fernandez, L., Agúndez, I., Mateo, A. M., Carrera, S., Gutiérrez, V., & Vaquero, C. (1999) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(99)70139-4 · Cited by 126
Noble, S., Shelley, M. D., Coles, B., Williams, S. M., Wilcock, A., & Johnson, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70149-9 · Cited by 109
Escriba, A., Maluenda, M. P., Rubio, M., Margalet, I., Lezana, A. H., Gallego, J., Ribera, J. M., & Veiga, F. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614067 · Cited by 107
Hull, R. D., Pineo, G. F., Brant, R., Liang, J. Q., Cook, R., Solymoss, S., Poon, M., & Raskob, G. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.023 · Cited by 107
Romera, A., Cairols, M. A., Vila-Coll, R., Martí-Mestre, X., Colomé, E., Bonell-Pascual, A., & Lapiedra, O. (2009) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2008.11.030 · Cited by 105
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
Crowther, M. A., & Warkentin, T. E. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03429.x · Cited by 98
Daskalopoulos, M. E., Daskalopoulou, S. S., Tzortzis, E., Sfiridis, P., Nikolaou, A., Dimitroulis, D., Kakissis, I., & Liapis, C. D. (2005) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2004.02.029 · Cited by 94
Prevention of Post-operative Deep Leg Vein Thrombosis in Patients with Cancer
Gallus, A. S. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657514 · Cited by 91
Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis
Gebska, M. A., KADZIOLA, Z. A., Saba, N., Carrasco, P., Kakkar, V. V., & on behalf of the Bemiparin Investigators (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613574 · Cited by 88
de Valk, H. W., Banga, J. D., Wester, J. W. J., Brouwer, C. B., van Hessen, M. W. J., Meuwissen, O. J. A. T., Hart, H. C., Sixma, J. J., & Nieuwenhuis, H. K. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-1-199507010-00001 · Cited by 88
Raskob, G. E., Buller, H. R., Prins, M. H., Segers, A. E. M., Shi, M., Schwocho, L. R., van Kranen, R., & Mercuri, M. F. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12230 · Cited by 88
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
Hull, R. D., Pineo, G. F., Brant, R., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.030 · Cited by 82
Riess, H. B., Pelzer, U., Hilbig, A., Stieler, J., Opitz, B., Scholten, T., Kauschat-Brüning, D., Bramlage, P., Dörken, B., & Oettle, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-361 · Cited by 81
From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer
Levine, M. N., Lee, A. Y., & Kakkar, A. K. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00275.x · Cited by 81
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Labedi, N., Barba, M., Terrenato, I., Sperati, F., Muti, P. C., & Schünemann, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub3 · Cited by 80
Self-citationLee, A. Y. Y., Bauersachs, R. M., Janas, M. S., Jarner, M. F., Kamphuisen, P. W., Meyer, G., & Khorana, A. A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-284 · Cited by 78
Rieß, H., Pelzer, U., Opitz, B., Stauch, M. B., Reitzig, P., Hahnfeld, S., Müller, L., Stieler, J., Dörken, B., & Oettle, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4033 · Cited by 76
Clinical Expertise in the Era of Evidence‐Based Medicine and Patient Choice (editorial)
Haynes, R. B., Pj, D., & Gh, G. (2002) · Vox Sanguinis · doi:10.1111/j.1423-0410.2002.tb05339.x · Cited by 67
Griffiths, G. O., Burns, S., Noble, S., Macbeth, F. R., Cohen, D. R., & Maughan, T. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-355 · Cited by 61
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism
Beckman, J. A., Dunn, K., Sasahara, A. A., & Goldhaber, S. Z. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613395 · Cited by 59
Partsch, H. (2001) · VASA · doi:10.1024/0301-1526.30.3.195 · Cited by 57
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
Cohen, A. T., Turpie, A. G. G., Leizorovicz, A., Olsson, C., Vaitkus, P. T., & Goldhaber, S. Z. (2007) · Vascular Medicine · doi:10.1177/1358863x07079017 · Cited by 57
Taliani, M. R., Agnelli, G., Prandoni, P., Becattini, C., Moia, M., Bazzan, M., Ageno, W., Tomasi, C., Guazzaloca, G., Ambrosio, G., et al. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00293.x · Cited by 54
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
Wester, J. P., de Valk, H. W., Nieuwenhuis, H. K., Brouwer, C. B., van der Graaf, Y., Meuwissen, O. J., Hart, H. C., Sixma, J. J., & Banga, J. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650643 · Cited by 53
Laporte, S., Liotier, J., Bertoletti, L., Kleber, F. X., Pineo, G. F., Chapelle, C., Moulin, N., & Mismetti, P. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04182.x · Cited by 51
External pneumatic compression and fibrinolysis in abdominal surgery
Cahan, M. A., Hanna, D. J., Wiley, L. A., Cox, D. K., & Killewich, L. A. (2000) · Journal of Vascular Surgery · doi:10.1067/mva.2000.107572 · Cited by 45
LACK OF EFFECT OF COUMARIN IN WOMEN WITH LYMPHEDEMA AFTER TREATMENT FOR BREAST CANCER
Oprinzi, C. H. L. L., Ugler, J. O. W. K., Eff, J., Ooke, T. H. W. R., Uella, S. U. K. Q., Ovotny, P. A. N., Owat, B. M., Ichalak, J. O. C. M., Tella, P., Evitt, R. A. L., et al. (1999) · Cited by 44
Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism
Kucher, N., Quiroz, R., McKean, S. C. W., Sasahara, A. A., & Goldhaber, S. Z. (2005) · Vascular Medicine · doi:10.1191/1358863x05vm634oa · Cited by 36
Low recurrence rate after deep calf‐vein thrombosis with 6 weeks of oral anticoagulation
Astermark, J., Björgell, O., Lindén, E., Lethagen, S., Nilsson, P. G., & Berntorp, E. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00318.x · Cited by 33
Romera-Villegas, A., Cairols-Castellote, M. A., Vila-Coll, R., Martí-Mestre, X., Colomé, E., & Iguaz, I. (2009) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2009.08.006 · Cited by 31
Kim, T., Kim, J., Mun, H. ‐., Lee, H., Roh, Y. H., Uhm, J., Pak, H., Lee, M., & Joung, B. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12810 · Cited by 29
Auer, R. C., Scheer, A. S., Wells, P. S., Boushey, R. P., Asmis, T., Jonker, D. J., & Carrier, M. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328349f1a8 · Cited by 27
Burgos, A., Alcaide, A., Alcoba, C., Jm, A. E., Garrido, J., Lorente, C., Moreno, E., Murillo, E., Olsina-Pavia, J., Kissler, J. J. O., et al. (1999) · PubMed · Cited by 26
Lundström, T., Wåhlander, K., Clason, S. B., Schulman, S., Eriksson, H., & for the THRIVE III Investigators (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-02-0096 · Cited by 24
Diagnosis and Treatment of Recurrent Venous Thromboembolism
Shattil, S. J. (1984) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31117-8 · Cited by 24
Long-Term Therapy of Venous Thromboembolism in Cancer Patients
Streiff, M. B. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0075 · Cited by 16
Treatment of Venous Thromboembolism in Cancer Patients
Lee, A. Y. Y., & Levine, M. N. (2005) · Cancer Control · doi:10.1177/1073274805012003s04 · Cited by 15
Pérez‐de‐Llano, L. A., Leiro‐Fernández, V., Golpe, R., et al. (2010) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283401406 · Cited by 14
Goodin, S. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050431 · Cited by 14
Management of thrombosis in the cancer patient.
Andrea, N. T., & Ansell, J. (2003) · PubMed · Cited by 12
Long-Term Anticoagulation Prophylaxis Following Acute Thromboembolism
Hyers, T. M. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.03.011 · Cited by 8
Dalteparin sodium in the management of thromboembolic disorders
Lee, A. Y. (2006) · Therapy · doi:10.1586/14750708.3.4.461 · Cited by 5
Optimizing the duration of anticoagulation therapy for venous thrombosis.
Solymoss, S. (1999) · Europe PMC (PubMed Central) · Cited by 3
Cited by
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Metadata
- Authors
- Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-07-08
- Volume
- 6
- Issue
- 7
- Pages
- CD006650-CD006650
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2132300233
- Cited by
- 428
- References
- 112
- FWCI
- 38.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.